Cargando…

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation

OBJECTIVE: The use of Durvalumab following chemoradiotherapy in patients with stage III NSCLC, considerably increased PFS (progression free survival) and OS (overall survival). Unfortunately, Durvalumab is currently not reimbursed for this indication in Lebanon so far. We have used Atezolizumab on a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saade, Lili Jose, Tfayli, Arafat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334090/ https://www.ncbi.nlm.nih.gov/pubmed/36974525 http://dx.doi.org/10.31557/APJCP.2023.24.3.737

Ejemplares similares

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer
por: Das, Millie, et al.
Publicado: (2023)

Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report
por: Yamakawa, Hideaki, et al.
Publicado: (2019)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer
por: Torresan, Sara, et al.
Publicado: (2023)

Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study
por: Jang, Jeong Yun, et al.
Publicado: (2021)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy
por: Barlési, F, et al.
Publicado: (2005)

Atezolizumab Plus Bevacizumab-induced Recalcitrant Pyoderma Gangrenosum Treated with Baricitinib: A Case Report
por: KIM, Han Seul, et al.
Publicado: (2023)

Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer
por: Kim, Myungsoo, et al.
Publicado: (2011)

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

The Pathology of the Pneumonic Lung
por: Sturges, Octavius
Publicado: (1873)

The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
por: Zhang, Tao, et al.
Publicado: (2020)

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer
por: Gilbert, Duncan C, et al.
Publicado: (2016)

Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy
por: Noda‐Narita, Shoko, et al.
Publicado: (2022)

Apparent diffusion coefficient agreement and reliability using different region of interest methods for the evaluation of head and neck cancer post chemo-radiotherapy
por: Anjari, Mustafa, et al.
Publicado: (2021)

Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment
por: Nakashima, Kei, et al.
Publicado: (2020)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Association of lung fluorodeoxyglucose uptake with radiation pneumonitis after concurrent chemoradiation for non-small cell lung cancer
por: Yue, Jinbo, et al.
Publicado: (2017)

Systematic risk analysis of radiation pneumonitis in breast cancer: role of cotreatment with chemo-, endocrine, and targeted therapy
por: Mangesius, Julian, et al.
Publicado: (2022)

Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer
por: Yang, Ju, et al.
Publicado: (2017)

Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report
por: Fakhri, Ghina, et al.
Publicado: (2017)

Rectum separation in patients with cervical cancer for treatment planning in primary chemo-radiation
por: Marnitz, Simone, et al.
Publicado: (2012)

Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer
por: Park, Young Hee, et al.
Publicado: (2013)

Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy
por: Neibart, Shane S., et al.
Publicado: (2023)

BAG1 down‐regulation increases chemo‐sensitivity of acute lymphoblastic leukaemia cells
por: Mariotto, Elena, et al.
Publicado: (2021)

The Shape of the Oral Glucose Tolerance Test-Glucose Response Curve in Islet Cell Antibody-Positive vs. -Negative Obese Youth Clinically Diagnosed with Type 2 Diabetes
por: Kim, Joon Young, et al.
Publicado: (2021)

Fournier Gangrene in a patient receiving chemo–radiation for rectal cancer
por: Pittaka, Maria, et al.
Publicado: (2018)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer
por: Coffey, David G., et al.
Publicado: (2022)

High-dose thoracic radiation therapy for non-small cell lung cancer: a novel grading scale of radiation-induced lung injury for symptomatic radiation pneumonitis
por: Szejniuk, Weronika Maria, et al.
Publicado: (2021)

Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL(CO) Correlate with Radiation Dosimetry and Pneumonitis Rate
por: Stana, Markus, et al.
Publicado: (2023)

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
por: Gridelli, C, et al.
Publicado: (2003)

Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
por: Jubb, A M, et al.
Publicado: (2011)

Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation
por: Munoz, Fernando, et al.
Publicado: (2007)

Cardiac and inflammatory biomarkers do not correlate with volume of heart or lung receiving radiation
por: Kuo, Angera H, et al.
Publicado: (2015)

Phospholipid membrane-decorated deep-penetrated nanocatalase relieve tumor hypoxia to enhance chemo-photodynamic therapy
por: Yin, Junjing, et al.
Publicado: (2020)

Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
por: Chirasuthat, Phatcharawat, et al.
Publicado: (2018)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k9n6qu9f41k8beg7drr4irvof3